Work

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Year: 2018

Type: article

Study design: Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(18)30082-2

Authors: Howard A Burris, Ian W Flinn, Manish R Patel, Timothy S Fenske, Changchun Deng, Danielle M Brander, Martin Gutierrez, James H Essell, John G Kuhn, Hari P Miskin, Peter Sportelli, Michael S Weiss, Swaroop Vakkalanka, Michael R Savona, Owen A O'Connor

Institutions: Sarah Cannon, Tennessee Oncology, Medical College of Wisconsin, NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, Columbia University, Duke Medical Center, Hackensack University Medical Center, Oncology Hematology Care, The University of Texas at San Antonio Health Science Center, TG Therapeutics, Inc. (United States), Rhizen Pharmaceuticals (Switzerland), Vanderbilt University Medical Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, TG Therapeutics

OpenAlex ID: W2788838674

FWCI: 17.54

Cites: 31

Cited by: 209

Related to: 10